DermTech, a La Jolla, California-based biotechnology company, raised $5.6m in the first close of a Series B financing.
The round was led by Jacobs Investment Company, LLC, with participation from existing and new investors.
The company intends to use the funds to further develop and complete commercial validation of assays, and achieve the necessary laboratory accreditation.
Led by John Dobak, M.D., Chief Executive Officer and President, DermTech is focused on the development of patented quantitative polymerase chain reaction (qPCR) assay technology and offers an RNA expression analysis of skin samples collected non-invasively using a tape collection kit.
The RNA from these cells is then isolated, amplified and analyzed using molecular biology tools to facilitate the assessment of cutaneous conditions.
The company, which is actively pursuing development of an assay that can determine RNA expression consistent with melanoma, plans to establish its own lab facility that will be certified pursuant to applicable Federal Clinical Laboratory Improvement Amendments (CLIA) regulations to process molecular tests and provide patient results.